These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 7927925

  • 1. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
    Xu FJ, Boyer CM, Bae DS, Wu S, Greenwald M, O'Briant K, Yu YH, Mills GB, Bast RC.
    Int J Cancer; 1994 Oct 15; 59(2):242-7. PubMed ID: 7927925
    [Abstract] [Full Text] [Related]

  • 2. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC.
    Clin Cancer Res; 1998 Oct 15; 4(10):2545-50. PubMed ID: 9796989
    [Abstract] [Full Text] [Related]

  • 3. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 15; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 4. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
    Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC.
    Int J Cancer; 1993 Feb 01; 53(3):401-8. PubMed ID: 7679090
    [Abstract] [Full Text] [Related]

  • 5. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
    Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC.
    Int J Cancer; 1999 Aug 12; 82(4):525-31. PubMed ID: 10404066
    [Abstract] [Full Text] [Related]

  • 6. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
    Zhou XX, Ji F, Zhao JL, Cheng LF, Xu CF.
    J Gastroenterol Hepatol; 2010 Jul 12; 25(7):1266-75. PubMed ID: 20594254
    [Abstract] [Full Text] [Related]

  • 7. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC.
    Clin Cancer Res; 2000 Aug 12; 6(8):3334-41. PubMed ID: 10955821
    [Abstract] [Full Text] [Related]

  • 8. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
    Shawver LK, Mann E, Elliger SS, Dugger TC, Arteaga CL.
    Cancer Res; 1994 Mar 01; 54(5):1367-73. PubMed ID: 7907001
    [Abstract] [Full Text] [Related]

  • 9. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.
    Cancer Res; 1994 Jul 15; 54(14):3758-65. PubMed ID: 7913407
    [Abstract] [Full Text] [Related]

  • 10. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
    Barbacci EG, Pustilnik LR, Rossi AM, Emerson E, Miller PE, Boscoe BP, Cox ED, Iwata KK, Jani JP, Provoncha K, Kath JC, Liu Z, Moyer JD.
    Cancer Res; 2003 Aug 01; 63(15):4450-9. PubMed ID: 12907618
    [Abstract] [Full Text] [Related]

  • 11. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.
    Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast RC.
    Cancer Res; 1991 Oct 01; 51(19):5361-9. PubMed ID: 1680547
    [Abstract] [Full Text] [Related]

  • 12. Cell growth regulation in epithelial ovarian cancer.
    Bast RC, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A.
    Cancer; 1993 Feb 15; 71(4 Suppl):1597-601. PubMed ID: 8431895
    [Abstract] [Full Text] [Related]

  • 13. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.
    Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD.
    Cancer Res; 1994 May 15; 54(10):2724-30. PubMed ID: 7909494
    [Abstract] [Full Text] [Related]

  • 14. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.
    Connelly PA, Stern DF.
    Proc Natl Acad Sci U S A; 1990 Aug 15; 87(16):6054-7. PubMed ID: 1974718
    [Abstract] [Full Text] [Related]

  • 15. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, Stoica A.
    Oncogene; 2003 Sep 11; 22(39):7998-8011. PubMed ID: 12970748
    [Abstract] [Full Text] [Related]

  • 16. Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells.
    Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G, Melani C, Ménard S.
    J Biol Chem; 2000 Feb 25; 275(8):5388-94. PubMed ID: 10681513
    [Abstract] [Full Text] [Related]

  • 17. Immunoselective cell growth inhibition by antibody-adriamycin conjugates targeting c-erbB-2 product on human cancer cells.
    Suzuki S, Tanaka M, Masuko T, Hashimoto Y.
    Biol Pharm Bull; 1995 Sep 25; 18(9):1279-82. PubMed ID: 8845823
    [Abstract] [Full Text] [Related]

  • 18. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M, Yao J, Yu D.
    Cancer Res; 1997 Mar 15; 57(6):1199-205. PubMed ID: 9067293
    [Abstract] [Full Text] [Related]

  • 19. Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer.
    Dean CJ, Eccles SA, Valeri M, Box G, Allan S, McFarlane C, Sandle J, Styles J.
    Cell Biophys; 1993 Mar 15; 22(1-3):111-27. PubMed ID: 7534210
    [Abstract] [Full Text] [Related]

  • 20. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
    Cao H, Decker S, Stern DF.
    Oncogene; 1991 May 15; 6(5):705-11. PubMed ID: 1675782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.